Terbium-based aguix-design nanoparticle to mediate x-ray-induced photodynamic therapy

16Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

X-ray-induced photodynamic therapy is based on the energy transfer from a nanoscin-tillator to a photosensitizer molecule, whose activation leads to singlet oxygen and radical species generation, triggering cancer cells to cell death. Herein, we synthesized ultra-small nanoparticle chelated with Terbium (Tb) as a nanoscintillator and 5-(4-carboxyphenyl succinimide ester)-10,15,20-triphenyl porphyrin (P1) as a photosensitizer (AGuIX@Tb-P1). The synthesis was based on the AGuIX@ platform design. AGuIX@Tb-P1 was characterised for its photo-physical and physico-chemical properties. The effect of the nanoparticles was studied using human glioblastoma U-251 MG cells and was compared to treatment with AGuIX@ nanoparticles doped with Gadolinium (Gd) and P1 (AguIX@Gd-P1). We demonstrated that the AGuIX@Tb-P1 design was consistent with X-ray photon energy transfer from Terbium to P1. Both nanoparticles had similar dark cytotoxicity and they were absorbed in a similar rate within the cells. Pre-treated cells exposure to X-rays was related to reactive species production. Using clonogenic assays, establishment of survival curves allowed discrimination of the impact of radiation treatment from X-ray-induced photodynamic effect. We showed that cell growth arrest was increased (35%-increase) when cells were treated with AGuIX@Tb-P1 compared to the nanoparticle doped with Gd.

Cite

CITATION STYLE

APA

Daouk, J., Iltis, M., Dhaini, B., Béchet, D., Arnoux, P., Rocchi, P., … Schohn, H. (2021). Terbium-based aguix-design nanoparticle to mediate x-ray-induced photodynamic therapy. Pharmaceuticals, 14(5). https://doi.org/10.3390/ph14050396

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free